email article
Stereotactic body radiotherapy (SBRT) proved safe for treating cancer patients with multiple metastases, according to a phase I trial.
In the NRG-BR001 trial, standard doses of SBRT were safe in 35 patients with oligometastatic breast, prostate, and non-small cell lung cancer (NSCLC) with a median of three or four metastases, or two within proximity to each other, reported Steve Chmura, MD, PhD, of University of Chicago Medicine, and colleagues.
Also, there were no protocol-defined dose-limiting toxicities in these patients at 180 days after the initiation of therapy, they stated in
However, the authors noted that a number of patients experienced late grade 3 adverse events (AEs), most likely related to the protocol therapy, which demonstrated the need for long-term follow-up with these patients.